MSMargot I. E. Slot

Margot I. E. Slot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Margot I. E. Slot has a total of 112 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Premorbid functioning trajectories and the one-year course of cognitive performance in first-episode psychosis: a cluster analysis in PSYSCAN

    by Margot I.E. Slot, Hendrika H. van Hell, Inge Winter-Van Rossum, George Gifford, Paola Dazzan, Arija Maat, Lieuwe De Haan, Benedicto Crespo-Facorro, Birte Y. Glenthøj, Colm McDonald, et al.


  • Open Access

    Effectiveness of Omega-3 Fatty Acids Versus Placebo in Subjects at Ultra-High Risk for Psychosis: The PURPOSE Randomized Clinical Trial

    by Inge Winter-Van Rossum, Margot I E Slot, Hendrika H van Hell, Matthijs G Bossong, Gregor Berger, Harald Aschauer, Arija Maat, Susanne Walitza, Orly Lavan, Inmaculada Baeza, et al.

    Background and Hypotheses: In the past 2 decades, substantial effort has been put into research on therapeutic options for people at ultra-high risk (UHR) for developing a first episode of psychosis (FEP), focusing on omega-3 polyunsaturated fatty acids (PUFAs) in preventing transition to psychosis. Despite an initial positive finding, subsequent studies failed to find a beneficial effect. The current study aimed to further investigate the effect of omega-3 PUFAs in UHR, to determine whether this line of research is worth pursuing. Study Design: A double-blind, randomized, placebo-controlled study testing the efficacy of 6-month treatment with omega-3 PUFAs in 135 subjects at UHR for FEP, aged 13 to 20 years on the prevention of a transition to psychosis, followed up for 18 months post-treatment. The trial was conducted at 16 general hospitals and psychiatric specialty centers located in 8 European countries and Israel. Study Results: There was no beneficial effect of treatment with omega-3 PUFAs compared to placebo; the rate of transition over 2 years did not differ between treatment arms nor was there a difference in change in symptom severity after 6-month treatment. Dropout rates and serious adverse events were similar across the groups. Conclusions: This is the third study that fails to replicate the original finding on the protective effect of omega-3 PUFAs in UHR subjects for transition to psychosis. The accumulating evidence therefore suggests that omega-3 PUFAs do not reduce transition rates to psychosis in those at increased risk at 2 years follow-up. Clinical Trials: This trial is registered with ClinicalTrials.gov (NCT02597439; Study Details | Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe | ClinicalTrials.gov).


  • Open Access

    Multivariable prediction of functional outcome after first-episode psychosis: a crossover validation approach in EUFEST and PSYSCAN

    by Margot I. E. Slot, Maria F. Urquijo Castro, Inge Winter - van Rossum, Hendrika H. van Hell, Dominic Dwyer, Paola Dazzan, Arija Maat, Lieuwe De Haan, Benedicto Crespo-Facorro, Birte Y. Glenthøj, et al.

    Several multivariate prognostic models have been published to predict outcomes in patients with first episode psychosis (FEP), but it remains unclear whether those predictions generalize to independent populations. Using a subset of demographic and clinical baseline predictors, we aimed to develop and externally validate different models predicting functional outcome after a FEP in the context of a schizophrenia-spectrum disorder (FES), based on a previously published cross-validation and machine learning pipeline. A crossover validation approach was adopted in two large, international cohorts (EUFEST, n = 338, and the PSYSCAN FES cohort, n = 226). Scores on the Global Assessment of Functioning scale (GAF) at 12 month follow-up were dichotomized to differentiate between poor (GAF current < 65) and good outcome (GAF current ≥ 65). Pooled non-linear support vector machine (SVM) classifiers trained on the separate cohorts identified patients with a poor outcome with cross-validated balanced accuracies (BAC) of 65-66%, but BAC dropped substantially when the models were applied to patients from a different FES cohort (BAC = 50–56%). A leave-site-out analysis on the merged sample yielded better performance (BAC = 72%), highlighting the effect of combining data from different study designs to overcome calibration issues and improve model transportability. In conclusion, our results indicate that validation of prediction models in an independent sample is essential in assessing the true value of the model. Future external validation studies, as well as attempts to harmonize data collection across studies, are recommended.


  • Open Access

    A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort

    by Margot I.E. Slot, Hendrika H. van Hell, Inge Winter-Van Rossum, Paola Dazzan, Arija Maat, Lieuwe de Haan, Benedicto Crespo-Facorro, Birte Glenthøj, Stephen M. Lawrie, Colm McDonald, et al.


  • Open Access

    Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials

    by Meenakshi Dauwan, Marieke J. H. Begemann, Margot I. E. Slot, Edwin H. M. Lee, Philip Scheltens, Iris E. C. Sommer

    We performed a meta-analysis to synthesize evidence on the efficacy and safety of physical exercise as an add-on therapeutic intervention for quality of life (QoL), depressive symptoms and cognition across six chronic brain disorders: Alzheimer’s disease, Huntington’s disease, multiple sclerosis, Parkinson’s disease, schizophrenia and unipolar depression. 122 studies ( = k) (n = 7231) were included. Exercise was superior to treatment as usual in improving QoL (k = 64,n = 4334, ES = 0.40,p < 0.0001), depressive symptoms (k = 60,n = 2909, ES = 0.78,p < 0.0001), the cognitive domains attention and working memory (k = 21,n = 1313, ES = 0.24,p < 0.009), executive functioning (k = 14,n = 977, ES = 0.15,p = 0.013), memory (k = 12,n = 994, ES = 0.12,p = 0.038) and psychomotor speed (k = 16,n = 896, ES = 0.23,p = 0.003). Meta-regression showed a dose–response effect for exercise time (min/week) on depressive symptoms (β = 0.007,p = 0.012). 69% of the studies that reported on safety, found no complications. Exercise is an efficacious and safe add-on therapeutic intervention showing a medium-sized effect on QoL and a large effect on mood in patients with chronic brain disorders, with a positive dose–response correlation. Exercise also improved several cognitive domains with small but significant effects.


  • Treating auditory hallucinations with transcranial direct current stimulation in a double-blind, randomized trial

    by Sanne Koops, Jan Dirk Blom, Ouarda Bouachmir, Margot I. Slot, Bas Neggers, Iris E. Sommer